Inactive Instrument

Press Releases Cyteir Therapeutics, Inc.

Equities

CYTT

US23284P1030

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq	03-07	BU
Cyteir Therapeutics - Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile	13/10/23	AQ
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile	12/10/23	BU
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	03/07/23	AQ
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	30/06/23	BU
CYTEIR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	05/06/23	AQ
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile	03/06/23	BU
CYTEIR THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	31/05/23	AQ
CYTEIR THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	10/05/23	AQ
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights	10/05/23	BU
CYTEIR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	03/04/23	AQ
CYTEIR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23/03/23	AQ
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights	23/03/23	BU
CYTEIR THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	06/02/23	AQ
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer	06/02/23	BU
CYTEIR THERAPEUTICS, INC. Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K/A)	03/02/23	AQ
CYTEIR THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	19/01/23	AQ
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway	19/01/23	BU
CYTEIR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	07/11/22	AQ
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights	07/11/22	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cyteir Therapeutics, Inc.

Equities

CYTT

US23284P1030

Press Releases

Filters